Lipocine granted Priority Motion by USPTO in Clarus interference case

Lipocine announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office, or USPTO, granted Lipocine’s Priority Motion in the interference case, Patent Interference No. 106,045, between Clarus Therapeutics U.S. Patent No. 8,828,428 and Lipocine, U.S. Patent Application No. 14/713,692, and entered adverse judgment against Clarus. The PTAB ruling cancels all claims of the Clarus ‘428 patent.
https://thefly.com/landingPageNews.php?id=2848107